Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean avobenzone and dimethoxy and octanoate and octisalate?
Displaying drugs 776 - 800 of 14497 in total

Penbutolol

Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … penbutolol and other diuretics …

Brigatinib

Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Description: … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and ... Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Botulinum toxin type B

Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Approved
Investigational
Matched Description: … and chromatography steps. ... The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin ... The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Eprosartan

Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system. By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced.
Approved
Matched Description: … By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs …
Matched Categories: … eprosartan and diuretics ... Angiotensin II receptor blockers (ARBs) and diuretics …

Tiaprofenic acid

Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the arylpropionic acid (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).
Approved
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Benzyl alcohol

Approved
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …

Osilodrostat

Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's...
Approved
Investigational
Matched Description: … Cushing's disease),[A191850] and was granted FDA approval and Orphan Drug designation in the US in March ... Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical ... L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and …
Matched Categories: … Sex Hormones and Insulins …

Flupentixol

Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid. Flupentixol is an antagonist of...
Approved
Investigational
Withdrawn
Matched Description: … [A229083] Flupentixol is an antagonist of both D1 and D2 dopamine receptors. ... It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. ... It is approved for use in Canada and other countries around the world, but not in the US. …

Pralsetinib

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Rotigotine

Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and …

Lurasidone

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
Approved
Investigational
Matched Description: … Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently …

Amlexanox

Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of...
Approved
Investigational
Withdrawn
Matched Description: … Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and ... aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and …
Matched Categories: … Alimentary Tract and Metabolism …

Gliquidone

Gliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.
Approved
Investigational
Matched Description: … + influx, and eventually increases insulin release. ... This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2 …
Matched Categories: … Alimentary Tract and Metabolism …

Teicoplanin

Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine...
Approved
Investigational
Matched Description: … antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and ... All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Idarucizumab

Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when...
Approved
Matched Description: … monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and ... Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Citalopram

Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the...
Approved
Matched Description: … It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing ... and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. ... A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and …

Tezacaftor

Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … consequently abnormal fluid and ion transport across cell membranes. ... [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Matched Categories: … ivacaftor and tezacaftor ... ivacaftor, tezacaftor and elexacaftor …

Ceftobiprole

Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Description: … infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative ... was subsequently approved in the United States with additional indications for skin and skin structure …

Lorpiprazole

Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Description: … Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive …

Axitinib

Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …

Secnidazole

Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once...
Approved
Matched Description: … to form a radical anion, thereby damaging and killing the target pathogen. ... It is structurally related to other 5-nitroimidazoles, including [DB00916] and [DB00911], but displays ... improved oral absorption and a longer terminal elimination half-life than other drugs in this class. …
Matched Categories: … azithromycin, fluconazole and secnidazole ... Antiparasitic Products, Insecticides and Repellents …

Aripiprazole lauroxil

Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors . Affecting about 1% of the...
Approved
Investigational
Matched Description: … It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and ... catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of emotional ... patients are faced with social stigma and discriminations. …
Matched Categories: … Aripiprazole and prodrugs …

Nintedanib

Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and ... agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and ... indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … , that exists in different isoforms and is often overexpressed in hematological malignancies. ... pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and ... PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Osimertinib

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs ... [A7927] More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 776 - 800 of 14497 in total